Compare Omnicom Group Inc. (OMC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs BIO-TECHNE Corp — how do they compare? Omnicom Group Inc. trades at $76.48 (market cap $20.97B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Omnicom Group Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays the higher dividend (4.19%). Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 63 Days and BIO-TECHNE Corp for 64 Days on average.
| OMC | TECH | |
|---|---|---|
Market Cap | $20.97B | $11.36B |
Volume | 2,092,899 | 5,390,331 |
Sector | Media | Health |
52-Week High | $88.94 | $72.61 |
52-Week Low | $67.27 | $43.31 |
Typical Hold Time | 63 Days | 64 Days |
Enterprise Value | $29.05B | $11.39B |
Dividend Yield | 4.19% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $76.45, up 2.11% with a bullish technical signal despite mixed earnings performance. The company shows strong revenue growth to $17.27B in 2025 but reported a net loss of -$54.5M. Analyst consensus is mixed with 32% buy ratings and a $100.50 price target, while recent news highlights leadership in digital marketing and $3.3B in new H1 2026 billings.
OMC presents a value opportunity with attractive P/S of 0.86 and dividend yield, though high P/E of 206.62 and recent net loss pose risks. Upside potential exists from AI capabilities and post-Interpublic synergies, but advertising market weakness and debt levels require monitoring for sustained recovery.
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
